Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

49.51
+0.70001.43%
Pre-market: 49.40-0.1100-0.22%07:12 EDT
Volume:1.73M
Turnover:84.48M
Market Cap:4.75B
PE:-7.65
High:49.95
Open:47.10
Low:47.10
Close:48.81
52wk High:78.48
52wk Low:30.04
Shares:95.99M
Float Shares:90.53M
Volume Ratio:1.09
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4700
EPS(LYR):-6.4700
ROE:-30.18%
ROA:-15.76%
PB:2.47
PE(LYR):-7.65

Loading ...

Crispr Therapeutics AG Faces Stock Price Slide

TIPRANKS
·
Nov 22, 2025

CRISPR Therapeutics (CRSP): Assessing Valuation After Recent Share Price Volatility

Simply Wall St.
·
Nov 20, 2025

Citizens JMP healthcare analysts hold an analyst/industry conference

TIPRANKS
·
Nov 19, 2025

Stock Track | CRISPR Therapeutics Soars 5.01% Amid M&A Rumor Highlighted in Betaville Blog

Stock Track
·
Nov 18, 2025

Crispr Therapeutics rumor highlighted in Betaville blog

TIPRANKS
·
Nov 18, 2025

Stock Track | CRISPR Therapeutics Soars 6.36% Amid Bullish Options Activity

Stock Track
·
Nov 15, 2025

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Nov 15, 2025

CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results

Simply Wall St.
·
Nov 13, 2025

Press Release: Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Dow Jones
·
Nov 13, 2025

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news
·
Nov 11, 2025

RBC Raises Price Target on CRISPR Therapeutics to $50 From $42, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 11, 2025

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 11, 2025

Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress

TIPRANKS
·
Nov 11, 2025

Merck's Heart Pill Slashes Cholesterol Levels in Test Patients -- Barrons.com

Dow Jones
·
Nov 11, 2025

Crispr Therapeutics price target lowered to $50 from $52 at Clear Street

TIPRANKS
·
Nov 11, 2025

Crispr Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Nov 11, 2025

Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)

TIPRANKS
·
Nov 10, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 10, 2025

CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

Benzinga
·
Nov 10, 2025

Earnings Flash (CRSP) CRISPR Therapeutics Posts Q3 Net Loss $1.17 a Share, vs. FactSet Est of $1.25 Loss

MT Newswires Live
·
Nov 10, 2025